Microsoft, SU2C seek to decrypt immune responses in cancer
Microsoft Corp. (NASDAQ:MSFT) and Stand Up To Cancer (Los Angeles, Calif.) partnered to use artificial intelligence to investigate factors that may contribute to a patient's immune response to cancer and cancer therapies. The news was announced at the SU2C Scientific Summit in Santa Monica.
The three-year SU2C Convergence 2.0 research initiative committed $11 million in total awards to seven multidisciplinary teams. The teams will work with Microsoft's AI and machine learning group to analyze multiple de-identified patient data sets -- including genome sequencing data, imaging studies, patient medical and medication records and laboratory values -- to determine factors that contribute to a patient's response to a specific treatment regimen. Factors under exploration will include DNA mismatch repair, tumor-specific proteins from mutated genes, cytokine function and natural killer cells...